Annovis Bio (ANVS) AI Stock Analysis

• Market Cap: $66.79M
• Dividend Yield: N/A
• Average Volume (3M): 322.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.27
• Revenue Growth: N/A
• EPS Growth: 62.84%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 26,502,890
• 10 Day Avg. Volume: 289,826
• 30 Day Avg. Volume: 322,873
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -291.71
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 659.92
• 1Y Price Target: $8.00
• Price Target Upside: 229.22% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.3
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $2.50 ▲(2.88% Upside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is primarily constrained by weak financial performance (no revenue, escalating losses, and persistent cash burn), implying continued reliance on external funding. Technicals are modestly negative with price below key moving averages and a negative MACD. A positive Phase 3 safety update provides some support, but the long runway to efficacy data and lack of meaningful valuation anchors (negative P/E, no dividend) keep the overall score low.

Positive Factors

Phase 3 safety nod (DSMB)

A DSMB recommendation that six-month safety data are acceptable and the trial can continue materially reduces regulatory and clinical development risk. Sustained safety across indications supports combined-data regulatory strategies, lowering long-term program uncertainty and de‑risking future filings.

No reported debt

A debt-free balance sheet lowers fixed financial obligations and reduces insolvency risk, preserving flexibility to pursue clinical development. Over the next several quarters this structural conservatism can ease refinancing pressure and improve strategic optionality despite cash burn.

Active Phase 3 enrollment & milestone visibility

Having a pivotal Phase 3 enrolling and a published readout timetable provides concrete milestone visibility. Tangible near-to-medium term catalysts can validate the mechanism and unlock regulatory discussions or partnerships, making program progress a durable operational positive.

Negative Factors

Pre-revenue profile

Absent product revenue, the company cannot internally fund R&D or operations, forcing reliance on external capital. Over a multi-quarter horizon this structural lack of top-line support leaves the business exposed to financing cycles and dilution risk until commercialization.

Persistent negative cash flow

Chronic negative operating and free cash flow, with accelerating burn, creates sustained financing pressure. This undermines balance sheet durability and increases the probability of equity raises or partnerships, which can dilute shareholders and constrain strategic freedom over months.

Equity volatility and prior negative equity

Historic equity volatility and instances of negative equity signal prior dilution and capital restructuring. Such instability can complicate future financing terms and investor confidence, making sustained capital access more costly and uncertain over the medium term.

Annovis Bio Business Overview & Revenue Model

Company Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

How the Company Makes Money

null

Annovis Bio Financial Statement Overview

Summary

Pre-revenue profile with persistent, worsening losses and consistently negative operating/free cash flow indicates elevated funding risk. The absence of reported debt is a meaningful positive, but volatile equity and increased cash burn weaken overall financial strength.

Income Statement

The company reports no revenue across the annual periods provided, consistent with a development-stage biotech. Losses are persistent and have been large, with net income negative every year and a very steep deterioration in the latest annual period (2025) versus prior years, indicating elevated spending and/or significant non-operating charges. With no top-line base and ongoing losses, profitability and earnings stability are weak.

Balance Sheet

A key positive is the absence of reported debt across all periods, reducing financial leverage risk. However, equity has been volatile (including negative equity in 2023) and returns on equity are highly unstable, reflecting recurring losses and a shifting capital base. The 2025 balance sheet shows substantially higher equity and assets versus 2024, but the sharp changes raise questions about durability and the need for continued funding given ongoing losses.

Cash Flow

Cash generation is weak: operating cash flow and free cash flow are negative in every year provided, implying ongoing cash burn to fund operations. Cash burn appears to have worsened materially in the last two annual periods (2024–2025) compared with earlier years, increasing financing dependence. While free cash flow tracks net income directionally, the overall profile indicates limited self-funding capacity.

Breakdown	Dec 2025	Mar 2025	Mar 2024	Mar 2023	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-29.70M	-26.69M	-45.03M	-25.51M	-14.50M
Net Income	-28.85B	-24.59M	-56.20M	-25.33M	-14.49M
Balance Sheet
Total Assets	21.08B	13.93M	10.21M	36.02M	46.00M
Cash, Cash Equivalents and Short-Term Investments	19.53B	10.55M	5.75M	28.38M	45.69M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	4.23B	4.62M	17.96M	7.70M	1.51M
Stockholders Equity	16.85B	9.31M	-7.75M	28.32M	44.49M
Cash Flow
Free Cash Flow	-25.62B	-21.89B	-39.97M	-17.31M	-9.13M
Operating Cash Flow	-25.62B	-21.89B	-39.97M	-17.31M	-9.13M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	34.60B	26.69B	17.34M	4.61K	46.74M

Annovis Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Negative. The current price of 2.43 is below the 20-day moving average (MA) of 2.55, below the 50-day MA of 2.84, and below the 200-day MA of 2.76, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 45.24 is Neutral, neither overbought nor oversold. The STOCH value of 23.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANVS.

Annovis Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WHWK	58 Neutral	$184.54M	-7.27	-10.35%	―	-42.62%	―
ABOS	54 Neutral	$198.08M	-0.98	-97.41%	―	―	-60.99%
DTIL	53 Neutral	$140.20M	-1.17	-95.12%	―	-99.07%	-10347.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANVS	45 Neutral	$66.79M	>-0.01	-0.68%	―	―	62.84%
COYA	45 Neutral	$94.79M	-11.27	-62.18%	―	-58.26%	-53.20%

Annovis Bio Corporate Events

Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod

On February 12, 2026, Annovis Bio said an independent Data and Safety Monitoring Board issued a positive safety recommendation at six months for its pivotal Phase 3 Alzheimer’s trial of buntanetap, allowing the U.S. study to continue without modification. The board found no safety concerns and reported that six-month safety data in Alzheimer’s patients were consistent with those previously seen in Parkinson’s patients, with further safety reviews scheduled at 12 and 18 months.

Management noted that alignment of safety outcomes across the Alzheimer’s and Parkinson’s programs has led regulators to indicate they may consider combined safety data in a future new drug application, potentially streamlining buntanetap’s path to market. The Phase 3 Alzheimer’s trial is currently recruiting and reported to be 40% complete, with the first symptomatic efficacy readout expected in early 2027 and a disease-modifying readout anticipated in early 2028, underscoring a long development runway for investors and patients.

The most recent analyst rating on (ANVS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.

Annovis Bio Hosts Regulation FD Investor Information Webinar

On January 28, 2026, Annovis Bio, Inc. held a webinar, supported by a prepared presentation that was made available to participants and stakeholders. The event signaled an effort by the company to formally communicate information to the market via a structured public forum, though no additional operational or strategic details were disclosed in the announcement.

The most recent analyst rating on (ANVS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.